CrushSCI.com
79.7平均天数
71.5中位天数
47最短天数
165最长天数
1182025发文量

Paper Review Records

全部论文审稿周期

20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

56 天

Upfront venetoclax plus quizartinib with low-dose cytarabine or azacitidine in older unfit patients with acute myeloid leukemia: the phase I/II VEN-A-QUI trial

作者
Juan Miguel Bergua; Pilar Lloret-Madrid; Rebeca Rodríguez-Veiga; Isabel Cano-Ferri; Ferran Vall-llovera; Antonio García-Guiñón; Joaquín Gómez-Espuch; Mercedes Colorado; Ignacio Casas-Avilés; Jordi Esteve; Antonia Sampol; María V. Verdugo; Ágata Almela; Marta Valero; Evelyn Acuña-Cruz; Blanca Boluda; Laura Torres; Joaquín Martínez-López; Eva Barragán; Teresa Cedena; Rosa Ayala; Beatriz Martín-Herreros; Bruno Paiva; David Martínez-Cuadrón; Pau Montesinos展开收起
作者单位
1. Hospital San Pedro de Alcántara, Cáceres, Spain; 2. Hospital Universitari i Politécnic La Fe, Valencia, Spain; 3. Hospital Universitari Mútua Terrassa, Barcelona, Spain; 4. Hospital Arnau de Vilanova, Lleida, Spain; 5. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; 6. Hospital Universitario Marqués de Valdecilla, Santander, Spain; 7. Hospital Clínic de Barcelona, Barcelona, Spain; 8. Son Espases University Hospital, IdISBa, Palma, Spain; 9. Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain; 10. Hospital Clínico de León, León, Spain; 11. Hospital Arnau de Vilanova, València, Spain; 12. Hospital 12 de Octubre, Universidad imas12, Complutense University, CNIO, Madrid, Spain; 13. Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada, Universidad de Navarra (CIMA), IDISNA, CIBER-ONC CB16/12/00369, Pamplona, Spain展开收起
PDF源文件 DOI 网页
69 天

Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR

作者
Kiavasch Mohammad Nejad Farid; Ute Hegenbart; Brigitte Neuber; Angela Hückelhoven-Krauss; Marc S. Raab; Carsten Müller-Tidow; Peter Dreger; Stefan Schönland; Anita Schmitt; Uta Elisabeth Höpken; Armin Rehm; Michael Schmitt展开收起
作者单位
1. Medical Faculty University of Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; 2. Department of Microenvironmental Regulation in Autoimmunity and Cancer, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany; 3. Department of Translational Tumorimmunology, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany展开收起
PDF源文件 DOI 网页
119 天

Adjuvant capecitabine-based oral chemotherapy plus trastuzumab as adjuvant therapy in patients with HER2-positive, node-negative breast tumors measuring 1 cm or smaller (ORCHID study)

作者
Min He; Lei Fan; Yi-Feng Hou; Guang-Yu Liu; Xiu-Zhi Zhu; Li Chen; Yin Liu; Wen-Jia Zuo; Gen-Hong Di; Can-Ming Chen; Zhen Hu; Jun-Jie Li; Kun-Yu Zhang; Li-Chen Tang; Jiong Wu; Yi-Zhou Jiang; Ke-Da Yu; Zhong-Hua Wang; Zhi-Ming Shao展开收起
作者单位
1. Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Shanghai, China; 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China展开收起
PDF源文件 DOI 网页
84 天

A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors

作者
Yuxiang Ma; Yufeng Guo; Shuang Deng; Haitao Lan; Suxia Luo; Keqiang Zhang; Qingqing Hu; Tao Fu; Pengxiang Wu; Qiuyue Cao; Luyang Zhao; Li Mao; Lieming Ding; Yan Huang; Yuanyuan Zhao; Yang Zhang; Jinhui Xue; Li Zhang; Hongyun Zhao展开收起
作者单位
1. Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Centre, Guangdong Provincial Clinical Research Centre for Cancer, Guangzhou, China; 2. Department of Oncology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China; 3. Phase I Clinical Research Center, Henan Cancer Hospital, Zhengzhou, China; 4. Department Five of Gynecological Oncology, Hunan Cancer Hospital, Changsha, China; 5. Betta Pharmaceuticals Co., Ltd, Hangzhou, China; 6. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Centre, Guangdong Provincial Clinical Research Centre for Cancer, Guangzhou, China展开收起
PDF源文件 DOI 网页
69 天

Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN- ZMYM2::FGFR1

作者
Tino Vollmer; Christoph Schell; Milena Pantic; Dietmar Pfeifer; Robert Zeiser; Khalid Shoumariyeh展开收起
作者单位
1. Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; 2. Institute of Surgical Pathology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany展开收起
PDF源文件 DOI 网页
165 天

Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor?

作者
Chantal Lucini; Isabella Sponseiler; Anna-Maria Bandian; Julia Senkiv; Thomas Lion展开收起
作者单位
1. St. Anna Children’s Cancer Research Institute (CCRI), Vienna, Austria; 2. Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; 3. Department of Pediatrics, Medical University of Vienna, Vienna, Austria; 4. St. Anna Children´s Cancer Research Institute, Vienna, Austria展开收起
PDF源文件 DOI 网页

FAQ

Journal of Hematology & Oncology审稿要多久?

截至2026-11-18,CrushSCI 收录了 Journal of Hematology & Oncology 的 20 篇完整审稿记录。最快一篇从收稿到录用用了 47 天(The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026,2026-06-04 收稿,2026-07-21 录用),最慢一篇用了 165 天;平均 79.7 天,中位数 71.5 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。